• June 16-19, 2025
  • Boston Convention & Exhibition Center

Shanghai Synergy Pharmaceutical Sciences Co., Ltd., A wholly owned subsidiary of Huahai Pharmaceutical Co., Ltd.

Loading

Shanghai Synergy Pharmaceutical Sciences Co., Ltd., A wholly owned subsidiary of Huahai Pharmaceutical Co., Ltd.

Monday, June 03, 2024
Company Presentation
Multiple Therapeutics
Company Presentation Theater 3
A clinical stage biotech company located at Zhangjiang Hi-Tech Park, Shanghai. The company is dedicated to innovative small molecule therapeutics research and development. Currently, the company has one drug candidate in Phase II study, two in Phase I study, and another one cleared for Phase I study. The areas of therapeutic focus are cardiovascular, anti-cancer, neuroscience, and autoimmune diseases.
Shanghai Synergy Pharmaceutical Sciences Co., Ltd., A wholly owned subsidiary of Huahai Pharmaceutical Co., Ltd.
Company Website: http://www.hhtpharm.com
Lead Product in Development: HHT201, Donepezil Pamoate long lasting injectable for treating Alzheimer's disease.
Number Of Unlicensed Products (For Which You Are Seeking Partners): 5

Company HQ City

Shanghai

Company HQ State

China

Company HQ Country

China

CEO/Top Company Official

Min Li, PhD, Board Chair

Development Phase of Primary Product

Phase I
Speakers
Min Li, PhD
Board Chair
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS